TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology (PERIO ) Clinical Trial Progress and Pre-clinical Research Developments DENVER and CHICAGO

TriSalus Life Sciences Highlights Pressure-Enabled

Regional Immuno-Oncology (PERIO ) Clinical Trial Progress and Pre-clinical Research Developments

DENVER and CHICAGO, December 15, 2022 - TriSalus Life

Sciences , Inc. ("TriSalus" or the "company"), an oncology company in the process of going public

through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (Nasdaq: MTAC)

("MedTech" or "MTAC"), today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional

Immuno-Oncology ("PERIO -01" and "PERIO -02") clinical program.

In recent months TriSalus has opened five new PERIO -01 (NCT04935229)

clinical trial sites, at Stanford University Hospitals, University of California Los Angeles, University of Colorado's Anschutz

Medical Campus, University of Washington Medical Center and University of Miami's Sylvester Comprehensive Cancer Center, in addition

to five previously activated sites. The PERIO -01 trial is studying an investigational drug, SD-101, delivered intravascularly

by the TriNav Infusion System ("TriNav ") using the company's proprietary

Pressure-Enabled Drug Delivery ("PEDD ") method of administration. The study is evaluating whether this

platform approach with SD-101 and PEDD can improve the performance of systemic checkpoint inhibitors in treating patients with

uveal melanoma with liver metastases. In addition to these U.S. sites, TriSalus anticipates opening future PERIOTM-01

clinical trial sites in the United Kingdom, Europe, and Canada.

In parallel, TriSalus opened PERIOTM-02 (NCT05220722) trial

sites at Columbia University and University of Colorado Denver, along with Rhode Island Hospital - which was announced last

month as part of an expanded research collaboration with Lifespan Health System. The PERIOTM-02 trial, expected to add additional

sites in 2023, is evaluating whether this same platform approach with SD-101 and PEDD can improve the performance of systemic

checkpoint inhibitors in treating patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma.

Both the PERIO -01 and PERIOTM-02 trials, which were

initiated at The University of Texas MD Anderson Cancer Center as part of a multi-year strategic collaboration agreement, are studying

the ability of SD-101 delivered by the PEDD method of administration to overcome two major challenges in treating patients with

liver and pancreatic tumors: immunosuppression and high intratumoral pressure. These two barriers can limit the delivery and efficacy

of therapeutics, such as immunotherapy drugs, from reaching their targets and result in poor outcomes.1,2,3,4,5

TriSalus recently shared initial findings from both clinical

studies, which indicate the potential of the company's therapeutic platform to improve immunotherapy outcomes for patients with

liver and pancreatic tumors.

The company has also published promising pre-clinical data in Cancer

Gene Therapy6 highlighting the potential of SD-101, a toll-like receptor 9 class C ("TLR9C") agonist,

to deplete or favorably reprogram myeloid-derived suppressor cells ("MDSCs") that have been shown to contribute to the limited

success of immunotherapy in the liver.7 The

lead author was Chandra Gosh, PhD, a biomedical scientist and project leader for TriSalus. Pre-clinical data was also presented at the

Society for Immunotherapy of Cancer's 37th Annual Meeting, which indicated that SD-101 has a distinct biologic profile

relative to other TLR agonists. The pre-clinical findings align with recently released clinical data which supported the potential that

SD-101 may reduce MDSCs in patient liver tumors.8,9,10

DaSilva NA, et al. Cell Death Discov. 2021;7(1):232.

Stylianopoulos T, et al. Cancer Res. 2013;73(13):3833-3841.

Zhang X, et al. PLoS ONE. 2019;14(12):e0225327.

Loeuillard E, et al. J Clin Invest. 2020;130(10):5380-5396.

Thorn M, et al. Cancer Gene Ther. 2016;23(6):188-198.

6 Ghosh, et al. Cancer

Gene Therapy. 2022 June 14 (online ahead of print).

Rev Cancer. 2021 July 29 (online ahead of print).

8 Ghosh, et al. Cancer

Gene Therapy. 2022 June 14 (online ahead of print).

Katz, Steven. (2022). 1165 Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells. Journal

for ImmunoTherapy of Cancer. 10. A1206-A1206. 10.1136/jitc-2022-SITC2022.1165.

10 TriSalus Life Sciences,

Inc. (2022 November 21). Form 8-K.

"The expansion of the PERIOTM-01 and PERIOTM-02

trials represents meaningful progress for our research program-extending trial access to patients across a broader geographic area

and increasing the number of partnerships with leading cancer centers," said Steven C. Katz, MD, FACS, Chief Medical Officer at

TriSalus. "Further, our pre-clinical work indicates a solid scientific foundation to inform our approach as we seek to advance

immunotherapy treatment options for patients with liver and pancreatic tumors. We look forward to building on this momentum for the PERIOTM

About TriSalus and Its Proposed Business Combination with MedTech

TriSalus is an oncology company integrating immunotherapy with disruptive

delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.

TriSalus' proprietary platform approach addresses immune dysfunction

in liver and pancreatic tumors by combining its highly effective drug delivery technology with immunotherapeutics. The TriSalus platform

comprises the TriNav Infusion System and SD-101, a class C toll-like receptor 9 ("TLR9") agonist. TriNav is an

FDA-cleared device that is designed to administer established and emerging therapeutics. SD-101, the company's investigational

TLR9 agonist, is being delivered via TriNav to selected sites, including tumors in the liver. TriNav is the latest TriSalus

asset for the proprietary PEDD method of administration which has been shown to overcome intratumoral pressure through modulation

of pressure and flow to increase delivery of therapeutic agents.

As announced on November 14, 2022, TriSalus has entered into a definitive

merger agreement with MedTech (the "Merger Agreement"), a publicly traded special purpose acquisition company in connection

with the proposed business combination and related transactions between the parties. Upon the closing of the transaction (expected to

occur in the first quarter of 2023), the combined company will be a publicly traded company and its common stock is expected to be listed

on the NASDAQ Stock Exchange under the ticker "TLSI". The transaction is subject to the satisfaction of the necessary regulatory

approvals and customary closing conditions, including the approval of MedTech's shareholders.

To learn more about clinical trial treatment protocol and enrollment,

visit http://www.periotrial.com or http://www.clinicaltrials.gov and search NCT04935229 or NCT05220722.

About MedTech Acquisition Corporation

MedTech is a blank check company formed for the purpose of effecting

a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses

or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.

Forward-Looking Statements

This communication contains certain "forward-looking statements"

within the meaning of the United States federal securities laws regarding MTAC's or TriSalus' expectations, hopes, beliefs,

assumptions, intentions or strategies regarding the future including, without limitation, statements regarding: (i) the tolerability

of SD-101 infusion with TriNav , (ii) the potential of TriSalus' proprietary PEDD method to enable SD-101 to have broad

immune effects in liver tumors and eliminate MDSC, (iii) expectations for continuing program development and potential outcomes, (iv)

TriSalus' ability to compete with other companies, and (v) expectations for topline data and regulatory approval. These forward-looking

statements generally are identified by words such as "anticipate," "believe," "continue," "could,"

"estimate," "expect," "intend," "may," "might," "plan," "possible,"

"potential," "predict," "project," "should," "strive," "would,"

"will" and similar expressions or the negative or other variations of such statements. These statements are predictions,

projections and other statements about future events that are based on various assumptions, whether or not identified in this communication

and on the current expectations of MTAC's and TriSalus' respective managements and are not predictions of actual performance

and, as a result, are subject to risks and uncertainties.

Many factors could cause actual results or developments to differ

materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business

Combination may not be completed in a timely manner or at all, which may adversely affect the price of MTAC's securities; (ii)

the risk that the Business Combination may not be completed by MTAC's business combination deadline and the potential failure to

obtain an extension of the business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business

Combination, including the approval of the Merger Agreement by the stockholders of MTAC, the satisfaction of the minimum cash amount

following any redemptions by MTAC's public stockholders, and the receipt of certain governmental and regulatory approvals, including

reimbursement approval; (iv) the lack of a third-party valuation in determining whether or not to pursue the Business Combination; (v)